A central communication channel for all Thomson Reuters pharmaceutical knowledge
July 2008
In the pharmaceutical industry, there's no such thing as a 'one size fits all'. Every organization is different, and that means that every user of Thomson Reuters data is different. What they all now have in common, however, is a single, central communication channel to tell them what's happening across the whole breadth of Thomson Reuters solutions.
INFOCUS is a bi-monthly email bulletin sent to all our pharmaceutical subscribers, highlighting everything Thomson Reuters is doing in this industry — the latest announcements about the solutions our users rely on, and where Thomson Reuters is providing the thought leadership that is increasingly fuelling pharmaceutical innovation around the world.
"It's an exclusive window into the latest news from Thomson Reuters," explains Jon Brett-Harris, executive vice president for the pharmaceutical and chemical markets. "Every two months, INFOCUS will help our subscribers make the most of their entitlement as a registered user of our solutions. We'll bring them free expert reports they can download, show how our commitment to their information needs powers constant development of our products, and provide invaluable advice on getting the most out of their knowledge investment."
And indeed, INFOCUS has started with a bang. In the first issue, released in May 2008, it highlighted the worldwide launch of the BIOMARKERcenter database, a single, comprehensive resource on biomarkers at all stages of development, accompanied by a thought leadership white paper ‘Establishing the standards in biomarker research'. With the launch of BIOMARKERcenter, Thomson Reuters is placed at the very forefront of pharmaceutical innovation.
In the same issue, Thomson Reuters was also able to announce that Thomson Pharma, its world leading pharmaceutical competitor intelligence solution, had won the 2008 Queen's Award for Enterprise in the innovation category.
The second edition of INFOCUS will be released in July.